“Cash attached” will be determined by the combo efficacy in clinical trials. You keep reposting your same weak shortsighted arguments over and over daily, as if certain corporate players (or market manipulators) can somehow override or overpower the gravitational forces of science indefinitely…
Consider that PD1 blockade and other immunotherapy technologies already have a massive foothold in the relatively new and rapidly expanding global immunotherapy market. Those forces span the globe and across all big pharma companies—they are forces greater than the market influence of any individual company alone. If dendritic cell technology proves effective in overcoming tumor resistance and unlocking the full potential efficacy of other technologies, such as PD1 blockade—which is already highly profitable—then DC technologies will secure a sizable share of the market too. The only way to stop the success of DC technologies would be to stop the sale of every other technology that is synergistically efficacious in combo with dendritic cell platforms.
“Big Pharma” may have significant power, but even they are at the mercy of the power of science, just like everyone else on Earth.
Not interested in your FUD games. TeamFUD twists every piece of good news and results into a lying FUD smokescreen, for their bosses to short behind. Partnerships or buyout will happen in due time and we'll patiently wait for it.
Market Data 
Markets 
